Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$0.27 - $0.5 $18,207 - $33,718
-67,436 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.37 - $0.54 $14,193 - $20,714
-38,361 Reduced 36.26%
67,436 $31,000
Q3 2021

Nov 15, 2021

SELL
$0.44 - $0.63 $1,658 - $2,375
-3,770 Reduced 3.44%
105,797 $47,000
Q2 2021

Aug 16, 2021

BUY
$0.48 - $0.72 $52,592 - $78,888
109,567 New
109,567 $66,000
Q1 2021

May 17, 2021

SELL
$0.68 - $1.25 $21,145 - $38,870
-31,096 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$0.38 - $0.78 $25,518 - $52,379
-67,153 Reduced 68.35%
31,096 $21,000
Q3 2020

Nov 16, 2020

SELL
$0.47 - $0.64 $99,652 - $135,696
-212,026 Reduced 68.33%
98,249 $46,000
Q2 2020

Aug 14, 2020

SELL
$0.41 - $0.73 $69,967 - $124,575
-170,652 Reduced 35.48%
310,275 $159,000
Q1 2020

May 15, 2020

BUY
$0.36 - $0.79 $84,028 - $184,395
233,412 Added 94.3%
480,927 $204,000
Q4 2019

Feb 14, 2020

BUY
$0.75 - $0.89 $89,856 - $106,630
119,809 Added 93.82%
247,515 $193,000
Q3 2019

Nov 14, 2019

BUY
$0.78 - $1.09 $31,237 - $43,652
40,048 Added 45.69%
127,706 $116,000
Q2 2019

Aug 14, 2019

BUY
$0.98 - $1.64 $62,642 - $104,830
63,921 Added 269.29%
87,658 $102,000
Q1 2019

May 15, 2019

SELL
$0.67 - $1.01 $75,643 - $114,030
-112,901 Reduced 82.63%
23,737 $0
Q4 2018

Feb 14, 2019

SELL
$0.63 - $1.0 $70,538 - $111,966
-111,966 Reduced 45.04%
136,638 $97,000
Q3 2018

Nov 13, 2018

BUY
$0.88 - $1.1 $206,154 - $257,692
234,266 Added 1633.88%
248,604 $0
Q2 2018

Aug 10, 2018

SELL
$0.91 - $1.45 $145,101 - $231,205
-159,452 Reduced 91.75%
14,338 $0
Q1 2018

May 11, 2018

BUY
$0.84 - $1.18 $82,725 - $116,209
98,483 Added 130.78%
173,790 $189,000
Q4 2017

Feb 09, 2018

BUY
$0.68 - $1.0 $11,132 - $16,371
16,371 Added 27.78%
75,307 $64,000
Q3 2017

Nov 09, 2017

BUY
$0.39 - $0.66 $22,985 - $38,897
58,936
58,936 $39,000

Others Institutions Holding PTN

About PALATIN TECHNOLOGIES INC


  • Ticker PTN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,290,480
  • Market Cap $16.9M
  • Description
  • Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...
More about PTN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.